Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Matthijs

Showing results (41-50 of 294) with videos related to

Pageof 30
Sort By:
Journal of the American College of Cardiology|January 10, 2015
Reply: statin-induced low low-density lipoprotein cholesterol level: is lower better?S Matthijs Boekholdt, G Kees Hovingh, David D Waters, et al.
European Heart Journal|August 6, 2010
C-reactive protein is a mediator of cardiovascular diseaseRadjesh J Bisoendial, S Matthijs Boekholdt, Menno Vergeer, et al.
Journal of Cardiac Surgery|January 24, 2020
Outcomes of cardiac surgery after mediastinal radiation therapy: A single-center experienceOnur B Dolmaci, Emile S Farag, S Matthijs Boekholdt, et al.
Human Genetics|August 28, 2003
Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysisS Matthijs Boekholdt, Ron J G Peters, Katerina Fountoulaki, et al.
Journal of the American College of Cardiology|September 1, 2018
Effect of Long-Term Low Lipoproteins on Neurocognitive FunctionRutger Verbeek, S Matthijs Boekholdt, Robert Luben, et al.
Journal of the American College of Cardiology|April 21, 2012
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)Samia Mora, Robert J Glynn, S Matthijs Boekholdt, et al.
Psychosomatic Medicine|August 30, 2008
Major depression, C-reactive protein, and incident ischemic heart disease in healthy men and womenPaul G Surtees, Nicholas W J Wainwright, S Matthijs Boekholdt, et al.
European Heart Journal|March 2, 2013
Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population studyBrigitte M Sondermeijer, S Matthijs Boekholdt, Jamal S Rana, et al.
Current Opinion in Lipidology|July 10, 2004
CETP gene variation: relation to lipid parameters and cardiovascular riskS Matthijs Boekholdt, Jan-Albert Kuivenhoven, G Kees Hovingh, et al.
Heart (British Cardiac Society)|January 18, 2015
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial diseaseRobert M Stoekenbroek, S Matthijs Boekholdt, Rana Fayyad, et al.
Pageof 30

Showing results (41-50 of 294) with videos related to

Sort By:
Pageof 30
Journal of the American College of Cardiology|January 10, 2015
Reply: statin-induced low low-density lipoprotein cholesterol level: is lower better?S Matthijs Boekholdt, G Kees Hovingh, David D Waters, et al.
European Heart Journal|August 6, 2010
C-reactive protein is a mediator of cardiovascular diseaseRadjesh J Bisoendial, S Matthijs Boekholdt, Menno Vergeer, et al.
Journal of Cardiac Surgery|January 24, 2020
Outcomes of cardiac surgery after mediastinal radiation therapy: A single-center experienceOnur B Dolmaci, Emile S Farag, S Matthijs Boekholdt, et al.
Human Genetics|August 28, 2003
Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysisS Matthijs Boekholdt, Ron J G Peters, Katerina Fountoulaki, et al.
Journal of the American College of Cardiology|September 1, 2018
Effect of Long-Term Low Lipoproteins on Neurocognitive FunctionRutger Verbeek, S Matthijs Boekholdt, Robert Luben, et al.
Journal of the American College of Cardiology|April 21, 2012
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)Samia Mora, Robert J Glynn, S Matthijs Boekholdt, et al.
Psychosomatic Medicine|August 30, 2008
Major depression, C-reactive protein, and incident ischemic heart disease in healthy men and womenPaul G Surtees, Nicholas W J Wainwright, S Matthijs Boekholdt, et al.
European Heart Journal|March 2, 2013
Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population studyBrigitte M Sondermeijer, S Matthijs Boekholdt, Jamal S Rana, et al.
Current Opinion in Lipidology|July 10, 2004
CETP gene variation: relation to lipid parameters and cardiovascular riskS Matthijs Boekholdt, Jan-Albert Kuivenhoven, G Kees Hovingh, et al.
Heart (British Cardiac Society)|January 18, 2015
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial diseaseRobert M Stoekenbroek, S Matthijs Boekholdt, Rana Fayyad, et al.
Pageof 30